Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Saurabh Zanwar(Mayo Clinic), Doris K. Hansen(Moffitt Cancer Center), Hamza Hashmi(Medical University of South Carolina), Aimaz Afrough(Southwestern Medical Center), Surbhi Sidana(Palo Alto University), Frederick L. Locke(Moffitt Cancer Center), Danai Dima(Fred Hutch Cancer Center), Shaji Kumar(Mayo Clinic), Yi Lin(Mayo Clinic), Leyla Shune(University of Kansas Medical Center), Shambavi Richard(Medical Oncology Hematology Consultants), Peter A. Forsberg(University of Colorado Denver), Omar Castañeda Puglianini(Moffitt Cancer Center), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Joseph P. McGuirk(University of Kansas Medical Center), Douglas W. Sborov(University of Utah), Gurbakhash Kaur(The University of Texas Southwestern Medical Center), Charlotte Wagner(University of Regensburg), Krina K. Patel(University of Vermont), Ciara L. Freeman(Moffitt Cancer Center), Larry Anderson(The University of Texas Southwestern Medical Center), Oren Pasvolsky(The University of Texas MD Anderson Cancer Center), Megan M. Herr(Roswell Park Comprehensive Cancer Center), Alex Lieberman-Cribbin(Icahn School of Medicine at Mount Sinai), Jack Khouri(Cleveland Clinic), James A. Davis(Medical University of South Carolina), Rebecca Gonzalez(Moffitt Cancer Center)
Cited by 46
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782